Hyperfine Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
11.1%projected annual EPS growth
Analyst Coverage
3analysts covering
FY Revenue (est.)
$20.2Mnext fiscal year
FY EPS (est.)
-$0.35next fiscal year
Monitoring Framework
Key Performance Indicators
Quarterly Revenue Growth Quarterly8,300.0%Target: 55% full-year growth midpoint
Commercial Swoop Systems Sold Quarterly10.0Target: Accelerating commercial adoption
Gross Margin Quarterly5,100.0%Target: 50% to 55% full-year target
Watch Items
- Cash Burn RateTrigger: Exceeding $28 million annuallyAction: Re-evaluate commercial expansion speed and operating expense structure.
- Contrast PMR Study Enrollment and FDA SubmissionTrigger: Delay in enrollment beyond 2026 targetAction: Assess clinical trial site performance and adjust regulatory timeline expectations.
Research as of 19 Jun 2026